Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Metabolism >  IDO inhibitors >  NLG919

NLG919

Basic information Safety Supplier Related

NLG919 Basic information

Product Name:
NLG919
Synonyms:
  • 5-(2-Cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,1-a]isoindole
  • NLG919(GDC-0919,Navoximod)
  • CS-820
  • GDC 0919
  • GDC0919
  • GDC-0919
  • NLG-919; NLG 919; IDO INHIBITOR;GDC-0919;GDC 0919;GDC0919
  • NLG919
CAS:
1402836-58-1
MF:
C18H22N2O
MW:
282.38
EINECS:
1592732-453-0
Product Categories:
  • Inhibitor
  • Inhibitors
Mol File:
1402836-58-1.mol
More
Less

NLG919 Chemical Properties

Melting point:
143 - 146°C
Boiling point:
524.6±33.0 °C(Predicted)
Density 
1.27±0.1 g/cm3(Predicted)
storage temp. 
-20°C
solubility 
Soluble in DMSO (up to 15 mg/ml)
form 
solid
pka
14.85±0.20(Predicted)
color 
White
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
More
Less

NLG919 Usage And Synthesis

Description

(±)-NLG-919 is an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor (Ki = 7 nM; EC50 = 75 nM). (±)-NLG-919 inhibits IDO-induced T cell suppression and restores T cell response during allogenic mixed lymphocyte reactions in vitro (ED50s = 80 and 120 nM, respectively). In vivo, (±)-NLG-919 induces a 95% reduction in tumor volume when administered in conjunction with a pmel-1 T cell vaccine. Formulations containing (±)-NLG-919 are under investigation in clinical trials for treatment of glioblastoma, melanoma, pancreatic, and breast cancers.

Uses

NLG919 is a potent indoleamine-2,3-dioxygenase (IDO) pathway inhibitor and is suitable for the treatment of immunosuppression associated with cancer.

target

IDO pathway

References

1) Mautino?et al.?(2013),?NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy;?Cancer Res.?73?issue 8 supplement?491 2) Li?et al.?(2014),?The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma;?J. Immunother. Cancer?2?21 3) Meng?et al.?(2017),?Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model;?Int. J. Immunopathol. Pharmacol.?30?215

NLG919Supplier

Shanghai JiYi Biotechnology Co. Ltd. Gold
Tel
13621943973
Email
sales@shjiyipharmatech.com
Jingmo (Xiamen) Biotechnology Co., Ltd Gold
Tel
13621943973; 13621943973
Email
sales@jamxmpharmatech.com
InvivoChem Gold
Tel
13549236410
Email
sales@invivochem.cn
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Energy Chemical
Tel
021-021-58432009 400-005-6266
Email
sales8178@energy-chemical.com